AbbVie gets positive CHMP opinion for upadacitinib to treat Crohn’s disease in adults
The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of AbbVie’s upadacitinib to treat adult patients suffering with moderately to severely active Crohn's disease.